Skip to main content
SpringerLink
Log in

Evaluating the Cost-Effectiveness of New Drugs: the “Setrons” as an Example

  • Conference paper
Antiemetics in the Supportive Care of Cancer Patients

Part of the book series: ESO Monographs ((ESO MONOGRAPHS))

  • 70 Accesses

Abstract

Therapeutic innovations inevitably have an impact on treatment budgets. Since the introduction of 5-HT3 receptor antagonists (“setrons”), the antiemetic budget has increased eight-fold from 1990 to 1992, which corresponds to an increase of 8% to 30% in the drug costs of hospital pharmacies [1], This suggests the need for economic analyses especially as health-care resources are limited and hospital policy makers have to make difficult choices in a climate of cost containment. Cost is not merely a currency transaction but reflects the consumption of a resource that could otherwise be used for another purpose.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Aapro MS, Kirchner V, Terrey JP: Is anticipatory nausea and vomiting a thing of the past. Br J Cancer 1994(69):957–960

    Article  PubMed  CAS  Google Scholar 

  2. Gralla RJ: Antiemetic treatment for cancer chemotherapy: problem and progress. Support Care Cancer 1994 (2):275–276

    Article  PubMed  CAS  Google Scholar 

  3. Dicato MA: Oral treatment with ondansetron in an outpatient setting. Eur J Cancer 1991 (27):S18–S19

    PubMed  Google Scholar 

  4. Hillman AL, Eisenberg JM, Pauly NV et al: Sounding board: avoiding bias in the conduct and reporting of cost-effectiveness research sponsored by pharmaceutical companies. N Engl J Med 1991 (324):1362–1365

    Article  PubMed  CAS  Google Scholar 

  5. Drummond MF and Davis L: Economic analysis alongside clinical trials: revisiting the methodological issues. Inst J Technol Assess Health Care 1991 (7):561–573

    Article  CAS  Google Scholar 

  6. Farewell to promising goodbuys? (editorial) Lancet 1991 (338):416–417

    Google Scholar 

  7. Miller JP: Use of cost-benefit analysis in promotional material. Lancet 1991 (338):823–824.

    Article  PubMed  CAS  Google Scholar 

  8. Thimothy A: Report of a conference: cost versus benefit in non-surgical management of patients with cancer. Br Med J 1988 (297):471–472

    Article  Google Scholar 

  9. Evans RG and Robinson BC: Surgical day care: measurements of the economic payoff. Can Med Ass J 1980(123):873–880

    PubMed  CAS  Google Scholar 

  10. Clark RA, Kris MG, Gralla JR, et al: Serotonin antagonists demonstrate antiemetic effectiveness without extrapyramidal symptoms: analysis of studies with 3 new agents in 155 patients. Proc Am Soc Clin Oncol 1990 (9):322

    Google Scholar 

  11. Cox F: Ondansetron — a cost-effective advance in anti-emetic therapy. In: Glaxo (ed) Ondansetron -Global experience and future potential. Palais des Congrès Internationaux, Lyon, France, 9 November 1992 pp 40–44

    Google Scholar 

  12. Cunningham D, Gore M, Davidson N et al: The real costs of emesis — An economic analysis of ondansetron vs metoclopramide in controlling emesis in patients receiving chemotherapy for cancer. Eur J Cancer 1993 (29A):303–306

    Article  PubMed  CAS  Google Scholar 

  13. Detsky AS NI: A clinician’s guide to cost-effectiveness analysis. Ann Intern Med 1990 (113):147–154

    PubMed  CAS  Google Scholar 

  14. Dexter F and Tinker JH: Analysis of strategies to decrease postanesthesia care unit costs. Anesthesiology 1995 (82):94–101

    Article  PubMed  CAS  Google Scholar 

  15. Rubenstein EB and Elting LS: Re-examination of clinical aspects of pharmacoeconomic analysis. Am J Hosp Pharm 1994 (51):2970–2973

    PubMed  CAS  Google Scholar 

  16. Rubenstein EB and Elting LS: Pharmacoeconomic analyses: whose perspective counts and costs the most? Am J Hosp Pharm 1994 (51):1564–1569

    PubMed  CAS  Google Scholar 

  17. Rubenstein EB, Elting L, Kurtin D, Mikhail O, Swint M: Outcome of antiemetic prophylaxis among outpatients receiving highly emetic chemotherapy (Abstract). Proc Annual Meeting Am Soc Clin Oncol 1994(13): A1526

    Google Scholar 

  18. Rubenstein EB: Costs and benefits of outpatient therapy. Support Care Cancer 1994 (2):307–311

    Article  PubMed  CAS  Google Scholar 

  19. Sackett DL and Gent M: Controversy in counting and attributing events in clinical trials. N Engl J Med 1979(26):1410–1412

    Article  Google Scholar 

  20. Sands R, Roberts JT, Marsh M et al: Low dose ondansetron and dexamethasone: a cost effective alternative to high dose metoclopramide/dexa-methasone/lorazepam in the prevention of acute cisplatin induced emesis. Clin Oncol 1992 (4):67–68

    Article  CAS  Google Scholar 

  21. Smith RN: Safety of ondansetron. Eur J Cancer Clin Oncol 1989 (25):547–550

    Google Scholar 

  22. Sox HC, Blatt MA, Higgins MC, Marton KI: Cost effectiveness analysis and cost benefit analysis. In: Sox HC, Blatt MA, Higgins MC, Marton KI (eds) Medical Decision Making. Butterworth-Heinemann, Stonehamm, MA 1988 pp 317–335

    Google Scholar 

  23. Stanley A: Meeting report. Delivering the benefits of anti-emetic innovation. Vol 4. Meribel, France 1993

    Google Scholar 

  24. Stoddart GL and Drummond MF: How to read clinical journals: VII. To understand an economic evaluation (part A). Can Med Assoc J 1984 (130):1428–1434

    Google Scholar 

  25. Stoddart GL and Drummond MF: How to read clinical journals: VII. To understand an economic evaluation (part B). Can Med Assoc J 1984 (130):1542–1549

    Google Scholar 

  26. Eisenberg JM, Glick H, Koffer H: Pharmacoeco-nomics: economic evaluation of pharmaceuticals. In: Strom BL (ed) Pharmacoepidemiology. Churchill Livingstone 1990 pp 325–350

    Google Scholar 

  27. Tanneberger ST, Lelli G, Martoni A et al: The antiemetic efficacy and the cost-benefit ratio of ondansetron calculated with a new approach of health technology assessment (real cost-benefit index). J Chemother 1992 (4):326–331

    PubMed  CAS  Google Scholar 

  28. Tigh M and Goodman S: Carboplatin versus cis-platin. Lancet 1988 (ii): 1372–1373

    Article  Google Scholar 

  29. Udvarhelyi IS, Colditz GA, Rai A et al: Cost-effectiveness and cost-benefit analyses in the medical literature: are the methods being used correctly. Ann Intern Med 1992 (116):238–244

    PubMed  CAS  Google Scholar 

  30. Warr D, McKinney S, Tannock I: Influence of measurement error on assessment of response to anticancer chemotherapy: proposal for new criteria of tumor response. J Clin Oncol 1984 (2):1040–1046

    PubMed  CAS  Google Scholar 

  31. Weinstein MC and Stason WB: Foundations of cost-effectiveness analysis for health and medical practices. N Engl J Med 1977 (296):716–721

    Article  PubMed  CAS  Google Scholar 

  32. Wodinsky H, DeAnglis C, Rusthoven J et al: Reevaluating the cost of outpatient cancer chemotherapy. Can Med Ass J 1987 (137):903–906

    CAS  Google Scholar 

  33. Yarbro JW: Changing cancer care in the 1990s and the cost. Cancer 1990 (67):1718–1727

    Google Scholar 

  34. Johnson N and Bosanquet N: Cost effectiveness of 5-hydroxytryptamine 3 receptor antagonists: a retrospective comparison of ondansetron and grani-setron. Anti-Cancer Drugs 1995 (6):243–249

    Article  PubMed  CAS  Google Scholar 

  35. Noble A, Bremer K, Goedhals L: A double-blind, randomised, cross-over comparison of granisetron and ondansetron in 5-day fractionated chemotherapy: assessment of efficacy, safety and patient preference. Eur J Cancer 1994 (8):1083–1088

    Article  Google Scholar 

  36. Sands R, Roberts JT, Marsh M et al: Low dose ondansetron and dexamethasone: a cost effective alternative to high dose metoclopramide/dexa-methasone/lorazepam in the prevention of acute cisplatin induced emesis. Clin Oncol 1992 (4):67–68

    Article  CAS  Google Scholar 

  37. Kirchner V, Aapro M, Alberto P et al: The cost-effectiveness of granisetron compared with meto-clopramide plus dexamethasone. Proc Am Soc Clin Oncol 1992 (11):379

    Google Scholar 

  38. Buxton MJ and O’Brien BJ. Economic evaluation of ondansetron: preliminary analysis using clinical trial data prior to price setting. Br J Cancer 1992 (19 Suppl):S64–67

    CAS  Google Scholar 

  39. Freund DA and Dittus RS: Principles of pharmaco-economic analysis of drug therapy. Pharmaco-Economics 1992 (1): 20–32

    Article  CAS  Google Scholar 

  40. Calman K, McVie J, Soukop M et al: Cost of outpatient chemotherapy. Br J Med 1978 (1):493–494

    Article  CAS  Google Scholar 

  41. Goodwin P, Feld R, Ward P et al: The cost of cancer therapy. Eur J Cancer 1990 (26):223–225

    Article  PubMed  CAS  Google Scholar 

  42. Jenett B and Buxton M: When is treatment for cancer economically justified? J Roy Soc Med 1990 (83):25–28

    Google Scholar 

  43. Miles D, Richards M, Reubens R: Cost-effectiveness of cancer chemotherapy. Cancer Topics 1990 (7): 141–142

    Google Scholar 

  44. Rees G: Cost-effectiveness in oncology. Lancet 1985 (ii): 1405–1428

    Article  Google Scholar 

  45. Goddard M: The real costs of emesis. Eur J Cancer 1993(29A):297–298

    Article  PubMed  CAS  Google Scholar 

  46. O’Brien BJ, Rusthoven J, Rocchi A et al: Impact of chemotherapy-associated nausea and vomiting on patients’ functional status and on costs: survey of five Canadian centres. Can Med Assoc J 1993 (149):296–302

    Google Scholar 

  47. Marty M, Pouillart P, School S et al: Comparison of the 5-hydroxytryptamine (serotonin) antagonist ondansetron (GR38032F) with high-dose metoclo-pramide in the control of cisplatin-induced emesis. N Engl J Med 1990 (322):816–821

    Article  PubMed  CAS  Google Scholar 

  48. Plosker GL and Richard JM: Ondansetron: a phar-macoeconomic and quality-of-life evaluation of its antiemetic activity in patients receiving cancer chemotherapy. PharmacoEconomics 1992 (2):285–304

    Article  PubMed  CAS  Google Scholar 

  49. Kirchner V, Aapro M, Terrey JP: Antiemetic treatment costs in chemotherapy: the economic evaluation of granisetron. ESMO XVII, Palais des Congrès Internationaux, Lyon, France 1992

    Google Scholar 

  50. Jones AL, Lee GJ, Bosanquet N: The budgetary impact of 5-HT3 receptor antagonists in the management of chemotherapy-induced emesis. Eur J Cancer 1992 (29A):51–56

    PubMed  CAS  Google Scholar 

  51. Johnson NE, Nash DB, Carpenter CE et al: Ondansetron: costs and resource utilization in a US teaching hospital setting. PharmacoEconomics 1993 (3): 471–481

    Article  PubMed  CAS  Google Scholar 

  52. Foltyn Smith C and Amen RJ: Comparison of seven methods of preparing and administering small-volume injections. Am J Hosp Pharm 1988 (45): 1896–1901

    Google Scholar 

  53. Wilder-Smith OH and Borgeat A: Etomidate vs pro-pofol for suspension laryngoscopies. Eur J Anaesthesiol 1991 (8):509

    PubMed  CAS  Google Scholar 

  54. Parker SE and Davey PG: Pharmacoeconomics of intravenous drug administration. PharmacoEconomics 1992 (1): 103–115

    Article  PubMed  CAS  Google Scholar 

  55. Borgeat A: Effects of Diprivan on nausea and vomiting. Ann Fr Anesth Reanim 1994 (13):576–578

    Article  PubMed  CAS  Google Scholar 

  56. Peto R, Pike MC, Armitage P et al: Design and analysis of randomized clinical trials requiring prolonged observation of each patient. I. Introduction and design. Br J Cancer 1976 (34):585–612

    Article  PubMed  CAS  Google Scholar 

  57. Glatstein E and Makuch RW: Illusion and reality: practical pitfalls in interpreting clinical trials. J Clin Oncol 1984 (2):488–497

    PubMed  CAS  Google Scholar 

  58. Rubenstein EB, Hauser AR, Rodriguez MA et al: Phase I-II trials of patient-controlled antiemetic therapy in cancer patients (Abstract). Proc Annual Meeting Am Soc Clin Oncol 1992 (11):A1378

    Google Scholar 

  59. Redelmeier DA and Tversky A: Discrepancy between medical decisions for individual patients and for groups. N Engl J Med 1990 (322): 1162–1164

    Article  PubMed  CAS  Google Scholar 

  60. Ried DL, McKenna DA, Horn JR: Meta-analysis of research on the effect of clinical pharmacokinetics services on therapeutic drug monitoring. Am J Hosp Pharm 1989 (46):945–951

    PubMed  CAS  Google Scholar 

  61. Blum KV, Abel SR, Urbanski CJ, Pierce JM: Medication error prevention by pharmacists. Am J Hosp Pharm 1988 (45): 1902–1903

    PubMed  CAS  Google Scholar 

  62. Dranitsaris G, Warr D, Puodziunas A: A randomized trial of the effects of pharmacist intervention on the cost of antiemetic therapy with ondansetron. Support Care Cancer 1995 (3):183–190

    Article  PubMed  CAS  Google Scholar 

  63. Drummond M, Stoddart G, Labelle R et al: Health economics: an introduction for clinicians. Ann Intern Med 1987 (107):88–92

    PubMed  CAS  Google Scholar 

  64. Ballatori E, Roila F, Berto P et al: Cost and cost-effectiveness analysis of ondansetron versus meto-clopramide regimens. A hospital perspective from Italy. PharmacoEconomics 1994 (5):227–237

    Article  PubMed  CAS  Google Scholar 

  65. Navari R, Gandara D, Hesketh P: Comparative clinical trial of granisetron and ondansetron in the pro-phylaxis of cisplatin-induced emesis. J Clin Oncol 1995 (13): 1242–1248

    PubMed  CAS  Google Scholar 

  66. Ruff P, Paska W, Goedhals L et al: Ondansetron compared with granisetron in the prophylaxis of cisplatin-induced acute emesis: a multicenter double-blind, randomised, parallel-group study. Oncology 1994 (51):113–118

    Article  PubMed  CAS  Google Scholar 

  67. Bonneterre J, Hecquet B et al: Granisetron (iv) compared with ondansetron (iv plus oral) in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy. A cross-over study. Eur J Cancer Clin Oncol 1996 (in press)

    Google Scholar 

  68. Gebbia V, Cannata G, Testa A et al: Ondansetron versus granisetron in the prevention of chemotherapy-induced nausea and vomiting: results of a prospective randomized trial. Cancer 1994 (74): 1945–1952

    Article  PubMed  CAS  Google Scholar 

  69. Jantunen I, Muhonen T, Kataja V: 5-HT3 receptor antagonists in the prophylaxis of acute vomiting induced by moderately emetogenic chemotherapy -a randomised study. Eur J Cancer 1993 (12):1669–1672

    Article  Google Scholar 

  70. Stewart A, McQuade B, Cronje J et al: Ondansetron compared with granisetron in the prophylaxis of cyclophosphamide-induced emesis in out-patients: a multicentre double-blind, double-dummy, randomised parallel-group. Emesis Study Group for Ondansetron and Granisetron in Breast Cancer Patients. Oncology 1995 (52):202–210

    Article  PubMed  CAS  Google Scholar 

  71. Johnson N and Bosanquet N: Cost effectiveness of 5-hydroxytryptamine3 receptor antagonists: a retrospective comparison of ondansetron and granisetron. Anticancer Drugs 1995 (6):243–246

    Article  PubMed  CAS  Google Scholar 

  72. Jobet I, Zyguel S, Prugnaud J: Economic evaluation of anti-5HT3: development of an economic model for cost minimisation study. J Pharm Clin 1995 (14): 243–249

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Cell Biology, Harvard Medical School, Alpert Building, 1st Floor, 200 Longwood Avenue, Boston, MA, 02115, USA

    Volker Kirchner

  2. Division of Signal Transduction, Beth Israel Hospital, Alpert Building, 1st Floor, 200 Longwood Avenue, Boston, MA, 02115, USA

    Volker Kirchner

  3. Divisione di Oncologia Medica, Istituto Europeo di Oncologia, via Ripamonti 435, 20141, Milano, Italy

    Matti S. Aapro

  4. Division d’Onco-Hématologie, Hôpital Cantonal Universitaire, 1211, Genève, Switzerland

    Matti S. Aapro

Authors
  1. Volker Kirchner
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Matti S. Aapro
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Medical Oncology Division, Policlinico Monteluce, Via Brunamonti, 06122, Perugia, Italy

    Maurizio Tonato M.D.

Rights and permissions

Reprints and permissions

Copyright information

© 1996 Springer-Verlag Berlin Heidelberg

About this paper

Cite this paper

Kirchner, V., Aapro, M.S. (1996). Evaluating the Cost-Effectiveness of New Drugs: the “Setrons” as an Example. In: Tonato, M. (eds) Antiemetics in the Supportive Care of Cancer Patients. ESO Monographs. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-80240-9_12

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-80240-9_12

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-80242-3

  • Online ISBN: 978-3-642-80240-9

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation